David S Ettinger
Overview
Explore the profile of David S Ettinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
7631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riely G, Wood D, Ettinger D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 May;
22(4):249-274.
PMID: 38754467
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance...
2.
Stevenson J, Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 Mar;
22(2):72-81.
PMID: 38503043
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States...
3.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski L, Murray J, et al.
Cancer Res Commun
. 2024 Feb;
4(3):786-795.
PMID: 38407352
Significance: In a large-scale, contemporary cohort of patients with advanced ALK-positive NSCLC, we evaluated molecular characteristics and their impact on acquired resistance mutations and clinical outcomes. Our findings that certain...
4.
Ghanem P, Murray J, Hsu M, Guo M, Ettinger D, Feliciano J, et al.
Clin Lung Cancer
. 2023 Dec;
25(2):109-118.
PMID: 38161136
Objectives: Understand from a real-world cohort the unique clinical and genomic determinants of a durable response to immune checkpoint inhibitors (ICIs). Materials And Methods: This is a retrospective study of...
5.
Murray J, Sivapalan L, Hummelink K, Balan A, White J, Niknafs N, et al.
Clin Cancer Res
. 2023 Nov;
30(2):389-403.
PMID: 37939140
Purpose: Although immunotherapy is the mainstay of therapy for advanced non-small cell lung cancer (NSCLC), robust biomarkers of clinical response are lacking. The heterogeneity of clinical responses together with the...
6.
Ghanem P, Murray J, Marrone K, Scott S, Feliciano J, Lam V, et al.
RMD Open
. 2023 Nov;
9(4).
PMID: 37914179
Purpose: Concomitant autoimmune rheumatic diseases (ARD) can add morbidity and complicate treatment decisions for patients with lung cancer. We evaluated the tumour characteristics at diagnosis and clinical outcomes in lung...
7.
Ettinger D, Wood D, Stevenson J, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2023 Sep;
21(9):961-979.
PMID: 37673108
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM)....
8.
Murray J, Sivapalan L, Hummelink K, Balan A, White J, Niknafs N, et al.
bioRxiv
. 2023 Jul;
PMID: 37425893
Purpose: Although immunotherapy is the mainstay of therapy for advanced non-small cell lung cancer (NSCLC), robust biomarkers of clinical response are lacking. The heterogeneity of clinical responses together with the...
9.
Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A, et al.
J Natl Compr Canc Netw
. 2023 Apr;
21(4):340-350.
PMID: 37015337
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known...
10.
Wang D, Harris J, Kraybill W, Eisenberg B, Kirsch D, Ettinger D, et al.
JAMA Oncol
. 2023 Mar;
9(5):646-655.
PMID: 36995690
Importance: Pathologic complete response (pCR) may be associated with prognosis in patients with soft tissue sarcoma (STS). Objective: We sought to determine the prognostic significance of pCR on survival outcomes...